GLPwatch

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

NCT04775082 · Active, not recruiting

Last updated 2026-05-28

This study is testing a new medicine to see how well it lowers weight in children who are obese.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 78 people Planned (estimated).
Who can join Ages 6–12 · all sexes
Timeline Started 2021-03 · est. completion 2027-02
Where 32 sites · Belgium, India, Israel, Malaysia, Mexico, Portugal, Russia, Switzerland, United States

What this study is testing ClinicalTrials.gov NCT04775082 ↗

Description as written by the study sponsor.

The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.

Treatments tested

Main thing measuredRelative change in BMI (Body mass index)
SponsorNovo Nordisk A/S
Conditions studiedObesity
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04775082 ↗